PUBLICATIONS
October 23, 2017

Fatty Acid Synthase Inhibitor TVB-3664 Reverses Multiple Components of Diet Induced Nonalcoholic Steatohepatitis in Mice Treated With or Without Co-Administered Pirfenidone and Reduces Collagen Accumulation in Bleomycin-Induced Murine Skin Fibrosis (Presented at The Liver Meeting 2017®, Washington, DC, Oct 20-24, Presidential Poster of Distinction, Abstract #1994).

Read More
PUBLICATIONS
October 23, 2017

Pharmacologic Inhibition of FASN Reverses Diet-Induced Steatohepatitis in Mice and Inhibits Lipogenesis in Humans (Presented at The Liver Meeting 2017®, Washington, DC, Oct 20-24, Abstract #1972).

Read More
PRESS RELEASES
October 16, 2017

3-V Biosciences to Present Clinical Data Demonstrating TVB-2640 Inhibits Fatty Acid Synthesis at The Liver Meeting 2017®

Menlo Park, California, October 16, 2017. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics for metabolic diseases and oncology, announced today that it will present data on its first-in-class…
Read More
PUBLICATIONS
May 2, 2017

Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for NASH treatment (Presented at The International Liver Congress, Amsterdam, NL April 18-23, 2017, Late Breaking Abstract LB427)

Read More
PUBLICATIONS
December 12, 2016

Heavily Pre-Treated Breast Cancer Patients Show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640 in Combination with Paclitaxel. (Presented at the San Antonio Breast Cancer Symposium on Saturday Dec. 10, 2016, abstract number P6-11-09)

Read More
PUBLICATIONS
November 11, 2016

Pharmacological inhibition of FASN Prevents High Fat Diet Induced Liver Damage in Mice and Significantly Reduces de novo Lipogenesis in Humans (Presidential Poster of Distinction presented at the AASLD Meeting on Sunday November 13, 2016, Abstract #1547)

Read More
PRESS RELEASES
November 8, 2016

3-V Biosciences to Present Data at the American Association for the Study of Liver Diseases Annual Meeting 2016 in Boston, MA

Menlo Park, California, November 04, 2016. 3-V Biosciences, Inc., a clinical-stage pharmaceutical company developing therapeutics for liver diseases, including non-alcoholic steatohepatitis (NASH), and oncology announced today that it has been…
Read More
PUBLICATIONS
November 8, 2016

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase Inhibitor, TVB-2640 (Presented at the NCRI Cancer Conference on Tuesday Nov. 8, 2016)

Read More
PUBLICATIONS
June 1, 2016

Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 (Poster and Poster Discussion Sessions at the ASCO Meeting on Sunday June 5, 2016, Abstract #2512, Board #212)

Read More
PUBLICATIONS
April 19, 2016

FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS-mutant NSCLC patients in a phase I study (Poster Presentation at AACR Meeting on Monday Apr 18, 2016 1:00 PM, Abstract number LB-214)

Read More